[ 177 Lu]Lu-PSMA-617 for mCRPC: Real-World Outcomes With and Without Concurrent ARPI (EANM 2026) - Sep 29, 2026 - Abstract #EP-0913; "In this real-world cohort of ARPI- and taxane-pretreated mCRPC patients, concurrent ARPI use during [177Lu]Lu-PSMA-617 did not independently improve clinical outcomes. These findings do not support the routine continuation of ARPI beyond progression at the time of radioligand therapy initiation."
Clinical • Real-world • Real-world evidence • Castration-Resistant Prostate Cancer • Prostate Cancer
|
|
M. Rust 1; D. Ventura 1; C. Backhaus 1; O. Platte 1; B. Matheja 1; M. Schäfers 1; M. Bögemann 2; L. Stegger 1; W. Roll 1; K. Rahbar 1
|